Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Polarean Imaging ( (GB:POLX) ).
Polarean Imaging Plc announced the issuance of a new Chinese patent for its Xenon MRI platform, allowing non-invasive visualization of pulmonary gas exchange and vascular function. This patent positions the company for potential future entry into the Chinese market, which faces significant challenges with lung diseases due to factors like air pollution and smoking. The Xenon MRI platform offers clinicians valuable insights into complex lung diseases, potentially improving early detection and disease monitoring, thus enhancing patient outcomes.
More about Polarean Imaging
Polarean Imaging Plc is a medical imaging technology company that focuses on improving pulmonary medicine by using MRI to directly visualize lung function. The company has developed XENOVIEW™, a hyperpolarized Xenon MRI inhaled contrast agent, which is FDA-approved in the United States. Polarean aims to address global unmet medical needs related to chronic respiratory diseases affecting over 500 million patients worldwide. The company is a leader in hyperpolarization science and is committed to developing and commercializing innovative imaging solutions, including a non-invasive and radiation-free pulmonary functional MRI platform.
YTD Price Performance: 5.00%
Average Trading Volume: 10,937
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $19.16M
See more insights into POLX stock on TipRanks’ Stock Analysis page.
